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Abstract: A library of glycoforms of human interleukin 6 (IL-
6) comprising complex and mannosidic N-glycans was gen-
erated by semisynthesis. The three segments were connected by
sequential native chemical ligation followed by two-step
refolding. The central glycopeptide segments were assembled
by pseudoproline-assisted Lansbury aspartylation and subse-
quent enzymatic elongation of complex N-glycans. Nine IL-6
glycoforms were synthesized, seven of which were evaluated
for in vivo plasma clearance in rats and compared to non-
glycosylated recombinant IL-6 from E. coli. Each IL-6
glycoform was tested in three animals and reproducibly
showed individual serum clearances depending on the structure
of the N-glycan. The clearance rates were atypical, since the
2,6-sialylated glycoforms of IL-6 cleared faster than the
corresponding asialo IL-6 with terminal galactoses. Compared
to non-glycosylated IL-6 the plasma clearance of IL-6 glyco-
forms was delayed in the presence of larger and multibranched
N-glycans in most cases
Introduction
Although many of the biological effects of the human
cytokine interleukin 6 (IL-6) have been studied in detail,[1]
little is known about the influence of the glycans present on
this glycoprotein. The glycan analysis of IL-6 isolated from
induced human blood monocytes revealed a relatively small
set of N-glycans, which were separated by gel filtration and
identified by glycosidase digestion.[2] The biological activity of
a glycoprotein is typically modified by the sugar part,[3]
however, homogenous glycoproteins (glycoforms) are rarely
accessible from natural sources and need to be accessed by
synthesis.[4] Following our semisynthetic approach to biolog-
ically active IL-6 glycoproteins[5] we planned to synthesize
a representative set of glycans of IL-6 and generate the
corresponding IL-6 glycoforms. Here we show for the first
time that each IL-6 glycoform has a different plasma half-live
showing either an increased or decreased clearance relative to
non-glycosylated IL-6 from E. coli.
IL-6 is a cytokine exerting both immunostimulating and
regenerating effects depending on the localization of the IL-6
receptor.[6] In vivo, IL-6 is mainly targeted to the liver[7] but
can also be complexed by a soluble, circulating IL-6
receptor.[8] When assayed with cells depending on IL-6 as
a proliferation stimulus the bioactivity of two IL-glycoforms
synthesized initially[5] was identical to non-glycosylated IL-6
from E. coli. We thus concluded that the N-glycan of IL-6
does not affect binding to the cellular IL-6 receptor. On the
other hand, the serum half-life of IL-6 in vivo should depend
on the type of oligosaccharide. Based on the glycan structures
identified earlier[2] we set out to provide a comprehensive
library of IL-6 glycoforms including complex-type and
oligomannosidic N-glycans for systematic studies.
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The main N-glycans identified on human IL-6[2] isolated
from mononuclear cells (Scheme 1b) were oligomannosidic
(40 %) or complex type (53% sialylated and & 6% neutral).
Among the mannosidic N-glycans an unusual paucimannosi-
dic Man2 tetrasaccharide was predominant (32%) followed
by a Man5 and a Man6 glycan (4 % each) and traces of Man8.
The main complex type N-glycan was biantennary and
sialylated (26%). The closely related core-fucosylated or
monogalactosylated biantennary N-glycans were less abun-
dant (11–17%). Only traces of a presumably triantennary
complex N-glycan were found (2%).
The structures envisioned for the library of synthetic IL-6
glycoforms are shown in Scheme 1c. We focused on the most
abundant N-glycans of each subtype and thus selected Man2
and Man5 from oligomannosidic structures as well as G2S2
from the complex type. Since the type of linkage of the
terminal sialic acids was not specified, we envisioned the
biantennary structures G2S2 in the 2,3- and the 2,6-sialylated
form. The effect of desialylation on IL-6 should be addressed




nary N-glycans were not im-
plemented in this study due to
their high similarity to the
major biantennary N-glycan.
The low abundance trianten-
nary N-glycan was not struc-
turally defined and may be
branched within the a1,3- or
the a1,6-arm. To consider
both possibilities and to gen-
erally investigate the effect of
additional N-glycan branches
on IL-6 we decided to incor-
porate tetraantennary N-gly-
cans with terminal GlcNAc
(Gn4), Gal (G4) or 2,6-linked
sialic acid residues (G4S4) as
a surrogate to maximize po-
tential steric and multivalency




For the semisynthesis of
the library of IL-6 glyco-
forms[5] three segments (A–
C) were employed (Scheme
1a). The functionalized seg-
ments A and C were obtained
recombinantly and the short
glycopeptide segment B was
synthesized convergently by
pseudoproline-assisted Lans-
bury aspartylation.[9] The required hexapeptide hydrazide[10]
3 (Scheme 2a) was assembled by Fmoc-SPPS and modified
after cleavage from the resin. In segment B the N-terminal
cysteine was protected by a mixed disulfide and the native
methionine at position 48 was replaced with a norleucine,[11]
thus preventing undesired oxidation.
Prior to coupling with aspartyl peptide 3 the glycosyl
amines G2,3,4,7,8 (Scheme 2b) were freshly prepared by
reduction of the corresponding azides.[12] Except the bianten-
nary compound[9b] all N-glycan azides were synthesized from
modular building blocks[13] followed by a multistep depro-
tection sequence yielding the desired unprotected N-glycan
azides. The key step in this sequence was an oxidative
debenzylation selectively removing all four benzyl groups in
the presence of the anomeric azide.[12a, 14]
For the paucimannosidic N-glycan azide 7 (Scheme S8)
a synthesis was developed based on the a-selective glycosy-
lation of a derivative of the core trisaccharide 5 with the
disaccharide imidate 6[15] The protected pentasaccharide 9
was deprotected to the corresponding free N-glycan azide 10
followed by an enzymatic removal of the accessory GlcNAc
Scheme 1. a) Retrosynthesis of IL-6 glycoforms; b) N-glycans detected in natural human IL-6 (values in
parentheses give percentage of total N-glycans and were deduced from ref. [2]); c) structures of N-glycans
envisioned for systematically varied library of hIL-6 glycoforms. The IL-6 glycoforms marked in bold (Gn
and G2) were available from previous work.[5]
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moiety as the final step (see supplementary information). The
disaccharide imidate 6 was preferred in this synthesis because
the glycosylations of the primary hydroxyl group with
peracetylated mannosyl donors gave rise to stable orthoesters,
which were resistant to rearrangement to the desired a-
mannoside and gave low yields in the deprotection to the
azide 7 (data not shown).
The coupling of the glycosyl amines G2,3,4,7,8 was
initiated by activating peptide 3 either with PyClock or
HATU/HOAt followed by addition of the sugars. The crude
products were deprotected and gave the glycopeptide hydra-
zides B2,3,4,7,8 in yields of 32–70 % after RP-HPLC. Due to
the pseudoproline at Ser 45 the formation of aspartimides[9]
was reliably reduced. The sialylated glycopeptides B5,6,9
were obtained by enzymatic sialylation[16] of B2 and B8 using
the bacterial sialyltransferases PdST6 or PmST3 and purified
by RP-HPLC. In all cases the sialylations required optimiza-
tion of the reaction conditions. For the 2,3-sialylation of B2
small amounts of PmST3 and short reaction time were
preferable whereas the 2,6-sialylations using PdST6 required
longer reaction times and repeat-
ed addition of CMP-NeuAc. The
final purification by RP-HPLC
readily separated intermediates
with incomplete sialylation.
The recombinant IL-6 pep-
tide 49–183 is not compatible
with the conditions for prepara-
tive purification by RP-HPLC
due to low recovery when apply-
ing acidic MeCN/water gradi-
ents.[5] Furthermore, the
Asp139-Pro140 bond is labile
under acidic conditions.[17] We
thus examined the use of the
disulfide-protected recombi-
nant[18] segment C (Scheme 3a).
The corresponding SUMO fusion
protein F[5] was cleaved with the
SUMO-protease SENP2 and the
free thiols were quantitatively
converted to mixed disulfides
using excess thiosulfonate
MMTS in 6 M GdmCl. After
the modification fragment C and
other proteins except SUMO
were precipitated by dialysis
against water. The precipitate
was dissolved in 6 M GdmCl
and purified over a Ni-NTA col-
umn, which retained the remain-
ing His6-tagged proteins (sub-
tractive Ni-IMAC). By adding
cysteine as a scavenger in the
proteolysis step the formation of
N-terminal thiazolidines on Cys
49 was efficiently blocked. This
protocol eliminated the need for
a subsequent acidic methoxya-
mine treatment, which previously gave rise to a cleavage
product at the Asp-Pro site within IL-6 49–183.[5] The N-
terminal 1–42 thioester A was obtained recombinantly from
the corresponding two-intein fusion protein.[5]
With all the segments in hand the native chemical
ligations were carried out sequentially in the C-terminal
direction.[5] Since the C-terminal amino acid of thioester A is
a threonine[19] the ligations with the seven glycopeptide
hydrazides B3–B9 were kept in an anaerobic tent for 4–8 days.
After purification by RP-HPLC the 1–48 glycopeptide
hydrazides D3–9 were obtained in yields of 47–79%. The
sialylated ligation products D5, D6, D9 were immediately
neutralized after purification by RP-HPLC with NH4HCO3 to
prevent loss of sialic acids during or after lyophilization.
The 1–48 glycopeptide hydrazides D3–9 were converted
to the corresponding thioesters[10] via diazotization followed
by addition of the benzylthiol MMBA.[5] Purification of the
thioesters E by gel filtration was generally preferable over
RP-HPLC since the product mixtures contained varying
amounts of thiolactone and mixed disulfide species. The seven
Scheme 2. a) Chemical and enzymatic synthesis of IL-6 glycopeptides B2–B9 ; b) glycosylamines G2,
G3, G4, G7,and G8 employed for coupling with 3.
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glycopeptide thioesters D3–9 were reacted with the protected
segment C and the ligations to the full length-IL-6 glycopep-
tides H3–9 were followed by LC-MS for 5–10 d. Prior to
refolding the ligation mixtures were reduced with DTT and
then rapidly diluted under anaerobic conditions. The refold-
ing mixture was subjected to a first gel filtration thereby
removing oligomers and low molecular weight impurities. The
disulfides of the refolded but still reduced IL-6 glycoproteins
(IL-63red–IL-69red, see supporting information) were subse-
quently oxidized in the presence of catalytic amounts of
cysteamine. In a final gel filtration, newly formed oligomers
were removed and the desired glycoforms IL-63–IL-69 were
obtained in high purity and good yields (24–35%).
The glycoforms were characterized by LC-MS, HR-MS,
SDS-PAGE and CD-spectroscopy indicating that the correct
fold was attained and the for-
mation of the disulfides was
complete (Scheme 4).
IL-6 is sensitive to partial
denaturation by organic sol-
vents,[17] which accounts for the
bimodal charge state distribu-
tion[20] commonly observed dur-
ing RP-HPLC-MS of the IL-6
glycoforms IL-63–IL-69 (Scheme
4a). In contrast a gaussian
charge state distribution was
obtained (indicating a native
fold of the glycoproteins)[20]
when injecting a desalted aque-
ous solution of the IL-6 glyco-
forms directly into the mass
spectrometer (Scheme 4b).[5]
This pattern was consistent
throughout the library of glyco-
forms. Additionally, an overlay
showed that the CD-spectra of
the glycoforms IL-63–IL-69 were
very similar to that of the non-
glycosylated reference IL-6 E.
coli (Schemenn4 c). The native
helical fold of the set of IL-6
glycoforms was independent of
the glycan and only the overall
intensity of the spectra varied to
a small extent (Scheme 4c).
We also attempted to crys-
tallize a synthetic IL-6 glyco-
form and started with IL-61.
After optimization of the crys-
tallization conditions[21] a crystal
structure was obtained from IL-
61 bearing a single GlcNAc moi-
ety, which was largely identical
to the non-glycosylated IL-6
from E. coli (pdbID:1ALU)
(Scheme 5a). The crystalliza-
tion of an IL-6 glycoform with
a full-length N-glycan (data not
shown) was not successful. The structure of IL-61 (GlcNAc)
did not resolve the flexible loop beyond Glu 50 (Ser 51-Asn
59) but refinement to 2.0 c showed low electron density for
the GlcNAc residue indicating connectivity at the side chain
amide (see Figure S84). Notably, in both structures the
unstructured loop region ends at Asn 60. However, the
largest deviations between the two structures were observed
around the glycosylation site at Asn44 reflecting an influence
of the glycosylation on the orientation of helix A prior to the
loop region (Scheme 5b,c).
The biological activity of all glycoforms IL-61–IL-69 was
compared by a proliferation assay using the IL-6-dependent
Ba/F3-gp130-hIL-6R cell line[5] (Scheme 6). Despite the
variations in the sugar part the activity of the individual
glycoforms was nearly identical in the cellular assays indicat-
Scheme 3. a) Recombinant expression of fusion protein F and conversion to disulfide-protected fragment
C ; b) native chemical ligation of segments A and B3–B9 to IL-6 (1–48) hydrazides D3–D9 and
conversion to thioesters E3–E9 ; c) native chemical ligation of thioesters E3–E9 with segment C followed
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ing that the binding to the IL-6 receptor and the formation of
the signal-transducing receptor complex[22] should not be
significantly affected by the various N-glycan structures.
To evaluate the biological activity of the library of IL-6
glycoforms in the bloodstream we set out for an exploratory
in vivo experiment with small rodents. The experimental
design required optimization and was finally carried out with
commercially available rats supplied with two implanted
catheters suitable for injections directly into the
bloodstream and repeated withdrawal of blood
samples. Non-glycosylated hIL-6 expressed in
E. coli is fully active in rats,[23] known to have
a short half-life (& 3 min) in the blood stream of
rats and is rapidly taken up by the liver or
washed out by the kidney.[7] We followed the
unlabeled hIL-6 glycoforms in the blood of the
rats via an ELISA-assay. To ascertain the
unbiased detectability of each IL-6 beforehand
250 pg of each glycoform was tested in the
ELISA sandwich assay. The results were nearly
identical for each IL-6 variant indicating that
the assay is not affected by the presence or the
structure of the N-glycans.
The individual dosage of each hIL-6 variant
was set to 8 mg per rat[23b] thus ensuring a suffi-
cient amount of detectable hIL-6 in the serum.
In total seven glycoforms were tested with IL-6
E. coli serving as a reference. After injection of
the IL-6 in 250 mL of PBS the animals behaved
normally and blood samples were taken over
20 minutes. Six blood samples (1–20 minutes)
were analyzed by ELISA in triplicates and the
residual amount of IL-6 was plotted against
time.
To assure that the measurements show
minimal influence by animal-to-animal varia-
bility the regime of exposure to different IL-6
glycoforms was as follows: A cohort of four rats
was exposed to four different IL-6 glycoforms
and the response in the blood was measured.
After a reconvalescence period of 7 days the
same cohort was exposed to the remaining four
glycoforms and after a second recovery period
the first four glycoforms were administered
again, but to different individuals. This set of
experiments was repeated with a second cohort
of animals allowing the measurement of a single
glycoform in three individuals.
Strikingly, all the IL-6 glycoforms tested
showed different plasma clearance rates. Rela-
tive to the reference IL-6 E. coli most glyco-
forms cleared slower, however, there were also
two glycoforms with a faster clearance
(Scheme 7). For better comparison of the inter-
secting curves we selected the 10 % of max
value as a reference threshold. Since the
measured clearances of the IL-6 glycoforms
were quite contrary to the expected ranking we
reconfirmed by ESI-MS that the samples used
for testing were correctly assigned and administered.
For the sialylated IL-6 glycoforms plasma clearance was
quite diverse. The most rapidly disappearing compound was
the biantennary 2,6-sialylated IL-65 whereas the correspond-
ing 2,3-sialylated IL-66 showed a much slower clearance[24]
followed by the 2,6-sialylated tetraantennary IL-68. Most
surprisingly, the galactosylated tetraantennary IL-69 had the
slowest clearance of all the glycoforms tested whereas the
Scheme 4. a) RP-HPLC-ESI-TOF-MS of glycoforms IL-63–IL-69 using acetonitrile/water
+ 0.1% HCOOH gradients. b) direct injections of desalted IL-63–IL-69 (plain water)
into ESI-TOF mass spectrometer show gaussian distribution of charge states; c) over-
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corresponding galactosylated biantennary IL-62 showed rapid
clearance. Among the mannosylated glycoforms the Man2
glycoform IL-63 showed rapid clearance (close to non-
glycosylated IL-6) whereas the Man5 glycoform IL-64 was
cleared slowly. Furthermore, only the two
glycoforms with tetraantennary N-glycans
(IL-68 and IL-69) showed bimodal clearance
curves.
The acute phase response of the admin-
istered variants of hIL-6 in the rats[23b] was
tested at the mRNA and the protein level
(see supporting information). mRNA of rat
acute phase proteins was detected by qRT-
PCR for fibrinogen-like protein 1 (FGL) >
orosomucoid > C-reactive protein. The
corresponding increase of orosomucoid in
plasma[23b] was shown by ELISA. The
biological responses appeared to be inde-
pendent of the carbohydrate of the IL-6
glycoforms.
We also tested the formation of the
hexameric signaling complex[22] IL-6/IL-6
receptor/GP-130 by biolayer interferome-
try. Data analysis of the complex binding
curves revealed similarly high affinities
(0.2–0.4 nM) for the respective complexes
containing IL-6 E.coli, IL-63 or IL-68, in-
dicating that small or large glycans on IL-6
do not substantially interfere with the
formation of the hexameric receptor com-
plex (see supporting information).
The main proteins mediating carbohy-
drate-related clearance of serum glycopro-
teins or neoglycoproteins from blood are
two lectins in the liver, the asialoglycopro-
tein receptor (ASGPR) and the mannose/
GlcNAc receptor (MR).[25] However, their
known specificities contradict the results obtained in our
study. Proteins with terminal galactose on multiantennary N-
glycans should clear faster than the sialylated variants via the
Scheme 5. a) Structure superposition of glycosylated IL-61 (PDB code
7NXZ, green) and non-glycosylated IL-6 (PDB code 1ALU, gray);
b) Ca-atom RMSD plot between both forms, showing the main
deviations around the glycosylation site (Asn 44); c) enlargement of
the Asn 44 glycosylation site containing helix A (Tyr 31 to Asn 44)
showing the gradually increasing deviation towards and beyond the
glycosylation site.
Scheme 6. Proliferation assay of IL-6 glycoforms IL-61–IL-69 using an
IL-6-dependent Ba/F3 cell line.
Scheme 7. Normalized percentage of hIL-6 glycoforms detected in rat serum after IV
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ASGPR (see IL-65 vs. IL-62 and IL-68 vs. IL-69). Similarly, the
MR should clear IL-64 faster than IL-63.
Due to the rapid clearance of IL-6 from blood (t1/2
& 3 min) a glycosidase-based degradation of the N-glycans
(observed after &24 h)[26] is unlikely to occur during the
plasma lifetime of the different IL-6 glycoforms. Thus, both
the faster and the slower plasma clearance of the IL-6
glycoforms relative to reference IL-6 E.coli can only be
a consequence of the different carbohydrate chains. We
assume the following scenario: Since reference IL-6 E.coli is
rapidly targeted to the liver the delayed clearance of most IL-
6 glycoforms should be caused by lectins in the plasma, on
blood cells or blood vessels. These may interact with the
glycans of the IL-6 glycoforms temporarily and thus delay
binding to the IL-6R during the liver passages. Besides
a soluble IL-6 receptor[27] (affecting all IL-6 variants equally)
blood serum of mammals also contains soluble versions of the
ASGPR,[28] MR,[29] the group of lectins of the lectin pathway
of complement activation[30] and various additional soluble
lectins.[31] These mostly multivalent lectins should preferen-
tially interact with IL-6 glycoforms bearing larger multi-
branched glycans and might cause a delayed targeting of
lectin-associated IL-6 glycoforms to the liver. The less
branched smaller glycans are presumably not well bound by
the serum lectins but may still be recognized by lectins in the
liver leading to an accelerated overall clearance of these
glycoforms. The serum concentration of the human lectins of
the lectin pathway of complement activation was found to be
in the range of 1–20 mgmL@1.[32] It can be assumed that the
equivalent lectins in rat[33] should be present in similar serum
concentrations. Thus, 8 mg of IL-6 administered to a rat with
a blood serum volume of & 10 mL[34] would lead to an initial
IL-6 concentration of & 1 mgmL@1 which is in the same order
of magnitude as the serum lectins mentioned above.
Remarkably, the IL-6 glycoforms with the slowest serum
clearance (IL-64, IL-68, IL-69) correspond to those present
only in low abundance in natural IL-6, whereas the fast-
clearing variants (IL-65, IL-63, IL-62) correspond to the most
abundant glycoforms of natural IL-6. The unexpected differ-
ences in the biological properties of the various IL-6 glyco-
forms could only be revealed by providing sufficient amounts
of a systematically varied library of synthetic IL-6 glycoforms.
Conclusion
In summary the chemoenzymatic semisynthesis of a sys-
tematic library of glycoforms of hIL-6 representing the most
abundant as well as the minor N-glycans found on natural IL-
6 was accomplished. The sequential ligations followed by
a two-step refolding/purification protocol was equally appli-
cable to all glycoforms. The resulting hIL-6 glycoproteins
were of high-purity and were properly folded according to
CD-spectroscopy, LC-MS, HR-MS and X-ray crystallography
(one structure). All glycoforms were equally active in
a cellular assay. The seven IL-6 glycoforms tested in rats
showed a wide range of different plasma clearance rates
markedly deviating from the expected ranking. This was
particularly evident for sialylated IL-6 glycoforms relative to
asialo glycoforms. In general, larger and multibranched N-
glycans led to slower plasma clearance. These findings show
that the natural microheterogeneity of the rapidly liver-
targeted cytokine IL-6 is strongly affecting its serum lifetime,
presumably mediated by interaction with endogenous soluble
or membrane-bound lectins.
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